Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Wockhardt Acquires French Generics Firm
May 14, 2007
| A version of this story appeared in
Volume 85, Issue 20
The Indian drug company Wockhardt has agreed to pay $265 million for Negma Laboratories, a French maker of generic drugs. With annual sales of about $150 million, Negma is France's fourth largest pharmaceutical firm, Wockhardt says. After integrating Negma, Wockhardt estimates that the European market will account for 60% of its sales. The Indian firm will now have four plants in Europe producing active pharmaceutical ingredients, injectable medicines, tablets, capsules, and creams. Negma is Wockhardt's third acquisition in the past year.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter